文献速递核素与放射性配体治疗肿瘤 PET/CT

局部晚期肝内胆管癌放射性栓塞治疗中3种不同治疗微粒的比较

Comparison of 3 Different Therapeutic Particles in Radioembolization of Locally Advanced Intrahepatic Cholangiocarcinoma.
PubMed 文献 · J Nucl Med · 2024-02-01

本研究报告比较用于局部晚期肝内胆管癌放射性栓塞治疗的3种治疗微粒(90Y玻璃微球、90Y树脂微球、166Ho标记聚左旋乳酸微球)。研究纳入6例90Y玻璃微球、8例90Y树脂微球和7例166Ho微球患者,采用治疗后定量PET/CT和SPECT/CT测定吸收剂量。结果显示90Y玻璃微球的肿瘤吸收剂量和治疗正常肝吸收剂量显著高于另两种微粒,而全正常肝吸收剂量、肿瘤与非肿瘤比值、毒性和疗效在三组间相似。

要点

  • 90Y玻璃微球的平均肿瘤吸收剂量为197 Gy,高于90Y树脂微球的73 Gy和166Ho微球的50 Gy。
  • 90Y玻璃微球的平均治疗正常肝吸收剂量为79 Gy,高于90Y树脂微球的37 Gy和166Ho微球的31 Gy。
  • 三组的毒性和疗效(依据RECIST 1.1和[18F]FDG PET总病灶糖酵解变化)相似。

核心结论

  • 用于放射性栓塞治疗的治疗微粒各不相同,在吸收剂量上显示出显著差异,而所有组的毒性和疗效相似。
  • 这一发现强调需要为每种微粒分别设定剂量约束和剂量目标。

研究设计与样本

  • 本研究比较用于局部晚期肝内胆管癌放射性栓塞治疗的3种治疗微粒。
  • 90Y玻璃微球、90Y树脂微球和166Ho标记聚左旋乳酸微球的处方活度按制造商推荐计算。
  • 纳入分析的患者为6例90Y玻璃微球、8例90Y树脂微球和7例166Ho微球。
  • 治疗后采用定量90Y PET/CT和定量166Ho SPECT/CT测定肿瘤吸收剂量、全正常肝吸收剂量、治疗正常肝吸收剂量、肿瘤与非肿瘤比值、肺吸收剂量和肺分流分数。
  • 疗效采用RECIST 1.1和基于[18F]FDG PET的总病灶糖酵解变化评估,肝毒性采用放射性栓塞诱导肝病分类评估。

主要发现

  • 平均给药活度:90Y玻璃微球为2.6 GBq,90Y树脂微球为1.5 GBq,166Ho微球为7.0 GBq。
  • 平均肿瘤吸收剂量:90Y玻璃微球197 Gy,90Y树脂微球73 Gy,166Ho微球50 Gy;90Y玻璃微球显著高于另两种微粒。
  • 平均治疗正常肝吸收剂量:90Y玻璃微球79 Gy,90Y树脂微球37 Gy,166Ho微球31 Gy;90Y玻璃微球显著高于另两种微粒。
  • 全正常肝吸收剂量和肿瘤与非肿瘤比值在各微粒间无显著差异。
  • 所有患者的肺吸收剂量均低于30 Gy,肺分流分数均低于20%。

关键数值与推荐

  • 处方活度按制造商推荐计算。
  • 疗效评估采用RECIST 1.1和基于[18F]FDG PET的总病灶糖酵解变化。
  • 肝毒性评估采用放射性栓塞诱导肝病分类。
  • 所有患者肺吸收剂量低于30 Gy,肺分流分数低于20%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our objective was to compare 3 different therapeutic particles used for radioembolization in locally advanced intrahepatic cholangiocarcinoma. Methods: 90Y-glass, 90Y-resin, and 166Ho-labeled poly(l-lactic acid) microsphere prescribed activity was calculated as per manufacturer recommendations. Posttreatment quantitative 90Y PET/CT and quantitative 166Ho SPECT/CT were used to determine tumor-absorbed dose, whole-normal-liver-absorbed dose, treated-normal-liver-absorbed dose, tumor-to-nontumor ratio, lung-absorbed dose, and lung shunt fraction. Response was assessed using RECIST 1.1 and the [18F]FDG PET-based change in total lesion glycolysis. Hepatotoxicity was assessed using the radioembolization-induced liver disease classification. Results: Six 90Y-glass, 8 90Y-resin, and 7 166Ho microsphere patients were included for analysis. The mean administered activity was 2.6 GBq for 90Y-glass, 1.5 GBq for 90Y-resin, and 7.0 GBq for 166Ho microspheres. Tumor-absorbed dose and treated-normal-liver-absorbed dose were significantly higher for 90Y-glass than for 90Y-resin and 166Ho microspheres (mean tumor-absorbed dose, 197 Gy for 90Y-glass vs. 73 Gy for 90Y-resin and 50 Gy for 166Ho; mean treated-normal-liver-absorbed dose, 79 Gy for 90Y-glass vs. 37 Gy for 90Y-resin and 31 Gy for 166Ho). The whole-normal-liver-absorbed dose and tumor-to-nontumor ratio did not significantly differ between the particles. All patients had a lung-absorbed dose under 30 Gy and a lung shunt fraction under 20%. The 3 groups showed similar toxicity and response according to RECIST 1.1 and [18F]FDG PET-based total lesion glycolysis changes. Conclusion: The therapeutic particles used for radioembolization differed from each other and showed significant differences in absorbed dose, whereas toxicity and response were similar for all groups. This finding emphasizes the need for separate dose constraints and dose targets for each particle.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Wagemans MEHM, Kunnen B, Stella M, et al. Comparison of 3 Different Therapeutic Particles in Radioembolization of Locally Advanced Intrahepatic Cholangiocarcinoma. J Nucl Med. 2024. PMID: 38176716. doi:10.2967/jnumed.123.265597

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。